These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34232070)

  • 21. Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses.
    Richard J; Prévost J; Baxter AE; von Bredow B; Ding S; Medjahed H; Delgado GG; Brassard N; Stürzel CM; Kirchhoff F; Hahn BH; Parsons MS; Kaufmann DE; Evans DT; Finzi A
    mBio; 2018 Mar; 9(2):. PubMed ID: 29559570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.
    Mayr LM; Decoville T; Schmidt S; Laumond G; Klingler J; Ducloy C; Bahram S; Zolla-Pazner S; Moog C
    Sci Rep; 2017 Oct; 7(1):12655. PubMed ID: 28978939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.
    Richardson SI; Chung AW; Natarajan H; Mabvakure B; Mkhize NN; Garrett N; Abdool Karim S; Moore PL; Ackerman ME; Alter G; Morris L
    PLoS Pathog; 2018 Apr; 14(4):e1006987. PubMed ID: 29630668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
    LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
    PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
    Rosenberg Y; Sack M; Montefiori D; Labranche C; Lewis M; Urban L; Mao L; Fischer R; Jiang X
    PLoS One; 2015; 10(3):e0120451. PubMed ID: 25807114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies.
    Boutin M; Vézina D; Ding S; Prévost J; Laumaea A; Marchitto L; Anand SP; Medjahed H; Gendron-Lepage G; Bourassa C; Goyette G; Clark A; Richard J; Finzi A
    mBio; 2022 Jun; 13(3):e0057722. PubMed ID: 35475646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells.
    Anand SP; Prévost J; Baril S; Richard J; Medjahed H; Chapleau JP; Tolbert WD; Kirk S; Smith AB; Wines BD; Kent SJ; Hogarth PM; Parsons MS; Pazgier M; Finzi A
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
    Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
    Front Immunol; 2018; 9():3163. PubMed ID: 30697215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.
    Forthal DN; Gach JS; Landucci G; Jez J; Strasser R; Kunert R; Steinkellner H
    J Immunol; 2010 Dec; 185(11):6876-82. PubMed ID: 21041724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-Induced Internalization of HIV-1 Env Proteins Limits Surface Expression of the Closed Conformation of Env.
    Anand SP; Grover JR; Tolbert WD; Prévost J; Richard J; Ding S; Baril S; Medjahed H; Evans DT; Pazgier M; Mothes W; Finzi A
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond Viral Neutralization.
    Lewis GK; Pazgier M; Evans DT; Ferrari G; Bournazos S; Parsons MS; Bernard NF; Finzi A
    AIDS Res Hum Retroviruses; 2017 Aug; 33(8):760-764. PubMed ID: 28084796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
    Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
    Front Immunol; 2021; 12():733958. PubMed ID: 34566999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies.
    Sok D; Laserson U; Laserson J; Liu Y; Vigneault F; Julien JP; Briney B; Ramos A; Saye KF; Le K; Mahan A; Wang S; Kardar M; Yaari G; Walker LM; Simen BB; St John EP; Chan-Hui PY; Swiderek K; Kleinstein SH; Alter G; Seaman MS; Chakraborty AK; Koller D; Wilson IA; Church GM; Burton DR; Poignard P
    PLoS Pathog; 2013; 9(11):e1003754. PubMed ID: 24278016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.
    Steichen JM; Kulp DW; Tokatlian T; Escolano A; Dosenovic P; Stanfield RL; McCoy LE; Ozorowski G; Hu X; Kalyuzhniy O; Briney B; Schiffner T; Garces F; Freund NT; Gitlin AD; Menis S; Georgeson E; Kubitz M; Adachi Y; Jones M; Mutafyan AA; Yun DS; Mayer CT; Ward AB; Burton DR; Wilson IA; Irvine DJ; Nussenzweig MC; Schief WR
    Immunity; 2016 Sep; 45(3):483-496. PubMed ID: 27617678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques.
    Parsons MS; Lee WS; Kristensen AB; Amarasena T; Khoury G; Wheatley AK; Reynaldi A; Wines BD; Hogarth PM; Davenport MP; Kent SJ
    J Clin Invest; 2019 Jan; 129(1):182-191. PubMed ID: 30475230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
    Rai MA; Blazkova J; Justement JS; Shi V; Kennedy BD; Manning MR; McLaughlin M; Sneller MC; Pau AK; Moir S; Chun TW
    EBioMedicine; 2024 Jun; 104():105151. PubMed ID: 38728839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.
    Richard J; Pacheco B; Gohain N; Veillette M; Ding S; Alsahafi N; Tolbert WD; Prévost J; Chapleau JP; Coutu M; Jia M; Brassard N; Park J; Courter JR; Melillo B; Martin L; Tremblay C; Hahn BH; Kaufmann DE; Wu X; Smith AB; Sodroski J; Pazgier M; Finzi A
    EBioMedicine; 2016 Oct; 12():208-218. PubMed ID: 27633463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.